Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)”

75 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 75 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05067140
What this trial is testing

ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer Metastatic
Novartis Pharmaceuticals 152
Testing effectiveness (Phase 2)Ended earlyNCT01681433
What this trial is testing

OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

Who this might be right for
Prostate CancerMetastatic Castrate-Resistant Prostate CancerPSA
Costantine Albany 72
Testing effectiveness (Phase 2)Looking for participantsNCT06001255
What this trial is testing

ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors

Who this might be right for
Metastasis Castration Resistant Prostate Cancer(mCRPC)
Hansoh BioMedical R&D Company 120
Early research (Phase 1)Study completedNCT01385228
What this trial is testing

Pazopanib, Docetaxel, Prednisone Prostate

Who this might be right for
Prostate Cancer
Daniel George, MD 36
Large-scale testing (Phase 3)Ended earlyNCT02057666
What this trial is testing

Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Ipsen 146
Early research (Phase 1)Study completedNCT05177042
What this trial is testing

Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer Metastatic
Arvinas Androgen Receptor, Inc. 45
Testing effectiveness (Phase 2)Ended earlyNCT02146833
What this trial is testing

SHIP (Selinexor in Hormone Insensitive Prostate Cancer)

Who this might be right for
Prostate Cancer
Karyopharm Therapeutics Inc 20
Testing effectiveness (Phase 2)Study completedNCT00942578
What this trial is testing

Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer

Who this might be right for
Metastatic Prostate Cancer
National Cancer Institute (NCI) 63
Testing effectiveness (Phase 2)Enrolling By InvitationNCT05570994
What this trial is testing

177Lu-HTK03170 in mCRPC With PSMA Positive Disease

Who this might be right for
Metastatic Castration-resistant Prostate CancerProstate Cancer MetastaticCastrate Resistant Prostate Cancer
British Columbia Cancer Agency 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT05114746
What this trial is testing

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 94
Large-scale testing (Phase 3)UnknownNCT05627752
What this trial is testing

Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage

Who this might be right for
Prostate CancerCastrate Resistant Prostate Cancer
Zhongnan Hospital 120
Early research (Phase 1)Looking for participantsNCT04729114
What this trial is testing

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Who this might be right for
Prostate CancerMetastatic Castration Resistant Prostate CancerMetastatic Castration-sensitive Prostate Cancer
Astellas Pharma Global Development, Inc. 174
Early research (Phase 1)Looking for participantsNCT03460977
What this trial is testing

Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)Small Cell Lung Cancer (SCLC)Follicular Lymphoma (FL)
Pfizer 453
Not applicableStudy completedNCT04516161
What this trial is testing

EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Bayer 1,180
Testing effectiveness (Phase 2)Active Not RecruitingNCT05658003
What this trial is testing

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 63
Early research (Phase 1)Study completedNCT01692262
What this trial is testing

Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.

Who this might be right for
Metastatic Castrate-Resistant Prostate Cancer (mCRPC),Efficacy,Safety and Tolerability,+3 more
AstraZeneca 59
Testing effectiveness (Phase 2)Study completedNCT01549951
What this trial is testing

Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Millennium Pharmaceuticals, Inc. 50
Not applicableStudy completedNCT02899104
What this trial is testing

Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Bayer 200
Testing effectiveness (Phase 2)WithdrawnNCT02035124
What this trial is testing

Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel

Who this might be right for
Advanced Prostate Cancer
SCRI Development Innovations, LLC
Early research (Phase 1)Study completedNCT02705469
What this trial is testing

ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer
Zenith Epigenetics 44
Load More Results